ArticleInfection and immunity2013
Candida albicans-Staphylococcus aureus polymicrobial peritonitis modulates host innate immunity.
Article in Infection and immunity, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
87 citing papers in PubMed, 147 citations in OpenAlex.
- Candida albicans activates Staphylococcus aureus virulence regulatory systems to drive toxin-mediated human cell death.PLoS pathogens · 2026Article
- Fungal-Bacterial Interactions in Polymicrobial Infections: Hidden Threats.MicrobiologyOpen · 2026Review
- Nasopharyngeal Bacterial-Fungal Dysbiosis in Respiratory-Diseased Endangered Forest Musk Deer (Biology · 2026Article
- Induction of myelopoiesis bymBio · 2025Article
- Understanding Heterogeneity and Tolerance of Dual Candida albicans-Staphylococcus aureus Biofilms to Cold Atmospheric Plasma and Antimicrobial Combinations.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2025Article
- Article
- Article
- A fungal metabolic regulator underlies infectious synergism during Candida albicans-Staphylococcus aureus intra-abdominal co-infection.Nature communications · 2024Article
- Can nonsteroidal anti-inflammatory drugs (NSAIDs) be repurposed for fungal infection?Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Protection against lethal sepsis following immunization withInfection and immunity · 2023Article
- Reappraisal of intra-abdominal candidiasis: insights from peritoneal fluid analysis.Intensive care medicine experimental · 2023Article
- The interactions of Candida albicans with gut bacteria: a new strategy to prevent and treat invasive intestinal candidiasis.Gut pathogens · 2023Review
- Article
- Differential Susceptibility of Mixed Polymicrobial Biofilms Involving Ocular Coccoid Bacteria (Microorganisms · 2023Article
- Oropharyngeal and intestinal concentrations of opportunistic pathogens are independently associated with death of SARS-CoV-2 critically ill adults.Critical care (London, England) · 2022Article
- Heme cross-feeding can augment Staphylococcus aureus and Enterococcus faecalis dual species biofilms.The ISME journal · 2022Article
- Polymicrobial biofilms of ocular bacteria and fungi on ex vivo human corneas.Scientific reports · 2022Article
- Review
- Real-time monitoring of mono- and dual-species biofilm formation and eradication using microfluidic platform.Scientific reports · 2022Article
- Inhibition of polymicrobial biofilm formation by saw palmetto oil, lauric acid and myristic acid.Microbial biotechnology · 2022Article
27 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Despite advances in medical device fabrication and antimicrobial treatment therapies, fungal-bacterial polymicrobial peritonitis remains a serious complication for surgery patients, those on peritoneal dialysis, and the critically ill. Using a murine model of peritonitis, we have demonstrated that monomicrobial infection with Candida albicans or Staphylococcus aureus is nonlethal. However, coinfection with these same doses leads to a 40% mortality rate and increased microbial burden in the spleen and kidney by day 1 postinfection. Using a multiplex enzyme-linked immunosorbent assay, we have also identified a unique subset of innate proinflammatory cytokines (interleukin-6, granulocyte colony-stimulating factor, keratinocyte chemoattractant, monocyte chemoattractant protein-1, and macrophage inflammatory protein-1α) that are significantly increased during polymicrobial versus monomicrobial peritonitis, leading to increased inflammatory infiltrate into the peritoneum and target organs. Treatment of coinfected mice with the cyclooxygenase (COX) inhibitor indomethacin reduces the infectious burden, proinflammatory cytokine production, and inflammatory infiltrate while simultaneously preventing any mortality. Further experiments demonstrated that the immunomodulatory eicosanoid prostaglandin E2 (PGE2) is synergistically increased during coinfection compared to monomicrobial infection; indomethacin treatment also decreased elevated PGE2 levels. Furthermore, addition of exogenous PGE2 into the peritoneal cavity during infection overrode the protection provided by indomethacin and restored the increased mortality and microbial burden. Importantly, these studies highlight the ability of fungal-bacterial coinfection to modulate innate inflammatory events with devastating consequences to the host.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.